Cognition Therapeutics Inc (CGTX) Stock Price & Analysis
Cognition Therapeutics Inc (CGTX) fell 4.24% to USD 0.92 as of July 25, 2026 at 07:11 UTC, according to Nexqual real-time market data.
CGTX last closed at USD 0.96; the session ranged USD 0.91–0.99 on volume of 443,079 shares. Market capitalization is $82.29M, with a 52-week range of USD 0.55–3.83 (NCM). Source: Nexqual, July 25, 2026 at 07:11 UTC.
Key Statistics (as of July 25, 2026 at 07:11 UTC)
| Price | USD 0.92 |
|---|---|
| Change | ▼ 4.24% (down) |
| Previous Close | USD 0.96 |
| Open | USD 0.96 |
| Day Range | USD 0.91 – 0.99 |
| 52-Week Range | USD 0.55 – 3.83 |
| Volume | 443,079 shares |
| Market Cap | $82.29M |
| Exchange | NCM |
Technical Analysis (CGTX)
Nexqual's technical model rates CGTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.91 (neutral) |
| vs SMA50 | Below (USD 1.17) |
| MACD | -0.07 (negative) |
Analyst Ratings (CGTX)
Wall Street analysts rate CGTX "None" based on 4 analysts, with a mean price target of USD 3.5 (range USD 3–4), per Nexqual as of July 25, 2026 at 07:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 3.5 |
| High Target | USD 4 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (CGTX)
| EPS Estimate | USD -0.06 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.07 ▲ beat |
| 2025-12-31 | USD -0.02 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.11 vs est -0.11 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Financials & Fundamentals (CGTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -92.82% |
| Debt / Equity | 1.56 |
| Current Ratio | 5.92 |
| Total Cash | $31.13M |
| Total Debt | $465,000 |
| Free Cash Flow | $-27.78M |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Financial Health Score (CGTX)
Nexqual rates Cognition Therapeutics Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $31M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -93%, ROA -89.8% |
Ownership (CGTX)
| Insider Ownership | +1.37% |
|---|---|
| Institutional Ownership | +25.02% |
| Shares Outstanding | 89.50M |
| Float | 81.83M |
| Short % of Float | +11.72% |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Leadership (CGTX)
Cognition Therapeutics Inc is led by Lisa Ricciardi (age 65), CEO, President & Director, per Nexqual as of July 25, 2026 at 07:11 UTC.
| CEO, President & Director | Lisa Ricciardi (age 65) |
|---|---|
| Chief Financial Officer | John Brendan Doyle (age 48) |
Major Backers & Investors (CGTX)
Notable institutional backers of Cognition Therapeutics Inc include Bios Capital Management, LP , Davenport & Co LLC, Renaissance Technologies, according to Nexqual as of July 25, 2026 at 07:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bios Capital Management, LP | 6.7% |
| Davenport & Co LLC | 4.76% |
| Renaissance Technologies | 1.25% |
| Chescapmanager LLC | 1.11% |
| Fidelity | 0.81% |
| Hilton Capital Management, LLC. | 0.61% |
| Dauntless Investment Group, LLC | 0.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.23% |
| BlackRock | 1.08% |
| Geode Capital | 1.03% |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
From Cognition Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
- Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
| XPON | Expion360 Inc. | USD 3.3 | ▼ 7.7% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
| UNCY | Unicycive Therapeutics, Inc. | USD 5.4 | ▼ 3.05% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:11 UTC. This page is informational and not investment advice.